文献速递冠心病

急性心肌梗死中高凝状态与纤溶受损的预后影响

Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究在连续接受经皮冠状动脉介入治疗(PCI)的患者中,依据疾病急性程度分组,用血栓弹力图(TEG)测量血栓生成指标,评估其与主要不良心血管事件(MACE)的关系。结果显示,急性心肌梗死(AMI)患者血小板-纤维蛋白凝块强度更高、纤溶活性更低,且高凝与低纤溶联合表型仅在AMI组中独立预测PCI后MACE。

要点

  • AMI患者较非AMI患者血小板-纤维蛋白凝块强度更高、纤溶活性更低。
  • MA≥68 mm且LY30<0.2%的联合表型仅在AMI组中独立预测PCI后MACE。
  • 该联合表型可能支持针对血栓生成性的个体化治疗以改善AMI预后。

核心结论

  • AMI的发生与高凝状态和纤溶受损显著相关,其联合表型仅在AMI患者中增加PCI后动脉粥样硬化血栓事件风险。

研究设计与样本

  • 从连续接受PCI的患者中纳入有血栓生成指标者共2705例,按疾病急性程度分为AMI组与非AMI组。
  • 血栓生成指标通过血栓弹力图(TEG)测量,血样在插入PCI鞘后立即获取,采样后4小时内完成TEG检测。
  • 评估MACE(心血管死亡、非致命性心肌梗死和非致命性卒中的复合终点),随访至多4年。

主要发现

  • AMI患者较非AMI患者最大振幅(MA)更高(66.5±7.8 vs. 65.3±7.2 mm,P<0.001)。
  • AMI患者较非AMI患者30分钟凝块溶解率(LY30)更低(0.9±1.8% vs. 1.1±1.9%,P<0.001)。
  • 指数AMI表现与MA相关(每增加1 mm:OR 1.024,95%CI 1.013-1.036,P<0.001),与LY30相关(每增加1%:OR 0.934,95%CI 0.893-0.978,P=0.004)。
  • 高血小板-纤维蛋白凝块强度(MA≥68 mm)与低纤溶活性(LY30<0.2%)的联合表型协同关联MACE发生。
  • 多变量分析中,MA≥68 mm且LY30<0.2%的联合表型是AMI组PCI后MACE的主要预测因素(校正HR 1.744,95%CI 1.135-2.679,P=0.011),但在非AMI组不显著(校正HR 1.031,95%CI 0.499-2.129,P=0.935)。

关键数值与推荐

  • 高凝状态定义为MA≥68 mm,低纤溶活性定义为LY30<0.2%。
  • MA每增加1 mm,AMI表现的OR为1.024(95%CI 1.013-1.036,P<0.001)。
  • LY30每增加1%,AMI表现的OR为0.934(95%CI 0.893-0.978,P=0.004)。

临床怎么用

  • 对AMI患者可考虑用TEG评估血栓生成性,识别MA≥68 mm且LY30<0.2%的高危联合表型。
  • 该联合表型或有助于筛选PCI后MACE风险更高的AMI患者,以支持针对血栓生成性的个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Atherothrombotic events are influenced by systemic hypercoagulability and fibrinolytic activity. The present study evaluated thrombogenicity indices and their prognostic implications according to disease acuity. METHODS AND RESULTS: From the consecutive patients undergoing percutaneous coronary intervention (PCI), those with thrombogenicity indices (n = 2705) were grouped according to disease acuity [acute myocardial infarction (AMI) vs. non-AMI]. Thrombogenicity indices were measured by thromboelastography (TEG). Blood samples for TEG were obtained immediately after insertion of the PCI sheath, and TEG tracing was performed within 4 h post-sampling. Major adverse cardiovascular events (MACE, a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) were evaluated for up to 4 years. Compared with non-AMI patients, AMI patients had higher platelet-fibrin clot strength [maximal amplitude (MA): 66.5 ± 7.8 vs. 65.3 ± 7.2 mm, P < 0.001] and lower fibrinolytic activity [clot lysis at 30 min (LY30): 0.9 ± 1.8% vs. 1.1 ± 1.9%, P < 0.001]. Index AMI presentation was associated with MA [per one-mm increase: odds ratio (OR): 1.024; 95% confidence interval (CI): 1.013-1.036; P < 0.001] and LY30 (per one% increase: OR: 0.934; 95% CI: 0.893-0.978; P = 0.004). The presence of high platelet-fibrin clot strength (MA ≥68 mm) and low fibrinolytic activity (LY30 < 0.2%) was synergistically associated with MACE occurrence. In the multivariable analysis, the combined phenotype of 'MA ≥ 68 mm' and 'LY30 < 0.2%' was a major predictor of post-PCI MACE in the AMI group [adjusted hazard ratio (HR): 1.744; 95% CI: 1.135-2.679; P = 0.011], but not in the non-AMI group (adjusted HR: 1.031; 95% CI: 0.499-2.129; P = 0.935). CONCLUSION: AMI occurrence is significantly associated with hypercoagulability and impaired fibrinolysis. Their combined phenotype increases the risk of post-PCI atherothrombotic event only in AMI patients. These observations may support individualized therapy that targets thrombogenicity for better outcomes in patients with AMI. CLINICAL TRIAL REGISTRATION: Gyeongsang National University Hospital (G-NUH) Registry, NCT04650529.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lee, Kim, Ahn, et al. Prognostic impact of hypercoagulability and impaired fibrinolysis in acute myocardial infarction. Eur Heart J. 2023. PMID: 36857519. doi:10.1093/eurheartj/ehad088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。